Clinical observation of oxaliplatin combined with S-1 or paclitaxel liposome in the treatment of advanced gastric cancer / 肿瘤
Tumor
;
(12): 92-98, 2015.
Artículo
en Chino
| WPRIM
| ID: wpr-848750
ABSTRACT
Objective:
To observe the clinical efficacy and adverse reactions of chemotherapy with oxaliplatin in combination with either S-1 or paclitaxel liposome as the first-line therapy for advanced gastric cancer.Methods:
Ninety-two patients with advanced gastric carcinoma were divided into two groups. In group A (46 cases), oxaliplatin combined with S-1 were administered. In group B (46 cases), oxaliplatin combined with paclitaxel liposome were administered. The shortterm curative effect, progression-free survival (PFS), overall survival (OS) and adverse reactions were observed and compared between the two groups.Results:
There were no significant differences in the objective response rate, disease control rate and median PFS between group A and group B (41.3% vs 45.7%, 73.9% vs 71.7%, 5.3 months vs 4.6 months; all P > 0.05). The median OS in group A and group B were 12.2 and 10.2 months, respectively, with a statistically significant difference (P < 0.05). The joint and muscle pain and neutropenia in group B were more severe than those in group A (P < 0.05).Conclusion:
These two chemotherapy regimens have the similar clinical efficacy for advanced gastric cancer, but oxaliplatin combined with S-1 could be superior to oxaliplatin plus paclitaxel liposome in OS and tolerance of chemotherapeutic toxicities.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Idioma:
Chino
Revista:
Tumor
Año:
2015
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS